$SNSS..Sunesis Pharmaceuticals Inc.'s vosaroxin is also in a late-stage Phase 3 trial, but as a second-line treatment in combination with cytarabine for relapsed or refractory acute myeloid leukemia. Vosaroxin is an antineoplastic quinolone derivative that is not a P-glycoprotein (P-gp) substrate, and may avoid the P-gp-mediated drug resistance seen in anthracyclines. The company expects to announce the Phase 3 data later this year in late Q3/early Q4.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.